WuXi AppTec acquires Oxgene, adding to its CGT capabilities
WuXi AppTec has completed the acquisition of Oxgene, a U.K.-based contract research and development organization that designs and develops scalable gene therapy technologies. The acquisition will allow WuXi to provide its customers with end-to-end support in the creation and development of cell and gene therapies (CGT), according to the company. Read More
Phio, AgonOx partner on T cell-based cancer immunotherapies
Phio Pharmaceuticals and AgonOx have announced a partnership to develop T cell-based cancer immunotherapies. Read More
Pharmaron expands CGT capabilities in U.K.
Pharmaron has purchased Allergan Biologics for $118.7 million from AbbVie, expanding its cell and gene therapy (CGT) capabilities in the U.K. Read More
SalioGen closes $20M to finance nonviral gene therapy development
SalioGen Therapeutics has closed $20 million in financing to advance its exact DNA integration technology platform for nonviral gene therapy. Read More
Veranome unveils complete spatial omics workflow
Veranome Biosystems has unveiled its complete sample-to-insight high-plex spatial omics workflow enabled by the company's Pisces technology. Read More
Rebus Biosystems debuts its Epser spatial omics platform
Rebus Biosystems has debuted its Esper spatial omics platform to advance the study of tissue biology and innovations in neuroscience, cancer, infectious disease, and immunology research. Read More
Vizgen launches integrated Merscope in situ imaging platform
Vizgen has launched its Merscope platform, a multiplexed, error-robust, single-cell in situ transcriptomic imaging technology. Read More
FDA clears Sarepta's Duchenne muscular dystrophy gene therapy
The U.S. Food and Drug Administration (FDA) has cleared casimersen, an antisense oligonucleotide, for the treatment of Duchenne muscular dystrophy in patients with a confirmed mutation amenable to exon 45 skipping. Read More
Artiva nabs $120M for NK cell therapies
Artiva Biotherapeutics has closed $120 million in financing to advance its natural killer (NK) cell therapy development programs and expand ongoing research and development activities. Read More
Saint-Gobain launches T cell-specific cell culture bags
Saint-Gobain Life Sciences has launched VueLife HP, a new high-permeability cell culture bag designed specifically for T cell-derived therapies. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter